ALFASIGMA SPA

Pharmas focus on Phase II companies, with 40% of M&A deals completed in under six weeks. Capital markets remain uncertain, leading to more private companies with advanced assets. Deals are more competitive, with mid-caps and European players becoming active acquirers.

Analysis of COBALT trial in PBC shows OCA significantly reduces risk of death, liver transplant, and hepatic decompensation compared to non-OCA treated patients, emphasizing the value of external control data in rare disease trials.

Analysis of COBALT trial shows OCA significantly reduces risk of death, liver transplant, and hepatic decompensation in PBC patients compared to non-OCA treated controls, highlighting the importance of external control data in rare disease trials.